2020-12-15
A signing ceremony was successfully held in Shanghai between Hanhui Pharma and GloriousMed for the exclusive commercial distributorship of the breast cancer precision diagnosis and treatment products in mainland China. Hanhui Pharma will provide marketing and sales services for GloriousMed to jointly promote the rapid development of the integration of breast cancer precision diagnosis and treatment.
2020-09-25
The People's Government of Zhejiang Province announced the list of “2019 Zhejiang Governmental Quality Award”. Hanhui Pharma become the only award-winning enterprise in the category of "Life and Health Industry”. It is reported that the "Zhejiang Governmental Quality Award" is the highest quality award in Zhejiang Province established by the People's Government of Zhejiang Province. It is a reward for organizations that engaged in product production, engineering construction, service provision, and environmental protection, and have implemented excellent performance management and achieved significant economic and social benefits. The award has been held for seven times. So far, Hanhui Pharma is the second pharmaceutical enterprise to win the honor.
2020-07-01
Hanhui Pharma announced it has entered into a strategic cooperation with WeDoctor Group (Zhejiang) Co., Ltd. The parties will jointly focus on chronic disease prevention, treatment and management, promote digital medical innovation and benefit more doctors and patients.
2020-03-20
Hanhui Pharma announced it has entered into a strategic cooperation agreement with Zai Lab to obtain the exclusive rights to promote Omadacycline Tosilate in mainland China. The collaboration, based on rich experience of Hanhui Pharma in promoting anti-infective products and leading pharmaceutical research and development capabilities of Zai Lab, will accelerate patients' access to Omadacycline Tosilate, the world's leading innovative anti-infective drug, thereby contributing to improving national health, extending human life span and improving quality of life.
2020-01-23
On January 23, Hisun Pharma and Hanhui Pharma donated 5,000 Solu-Medrol (Methylprednisolone Sodium Succinate for Injection 40 mg), 500 Junte (Imipenem and Cilastatin Sodium for Injection 1.0 g) and 100 Lixing (Tigecycline for Injection) for Wuhan Pulmonary Hospital, which could benefit 400 patients.
2020-01-20
Hanhui Pharma has reached a strategic cooperation agreement with Sinopharm Chuankang Pharmaceutical Co., Ltd. Since January 1, 2020, Zhejiang Ruihai Medicine Co., Ltd., a subsidiary of Hanhui Pharma, has been granted the exclusive right to promote, advertise and distribute Miwei® (Midodrine Hydrochloride Tablets) in mainland China, i.e. it has the resale and redistribution rights for the product. Miwei® (Midodrine Hydrochloride Tablets) is an exclusive, medically insured product for the treatment of hypotension and female stress urinary incontinence in China.
2020-12-15
A signing ceremony was successfully held in Shanghai between Hanhui Pharma and GloriousMed for the exclusive commercial distributorship of the breast cancer precision diagnosis and treatment products in mainland China. Hanhui Pharma will provide marketing and sales services for GloriousMed to jointly promote the rapid development of the integration of breast cancer precision diagnosis and treatment.
2020-09-25
The People's Government of Zhejiang Province announced the list of “2019 Zhejiang Governmental Quality Award”. Hanhui Pharma become the only award-winning enterprise in the category of "Life and Health Industry”. It is reported that the "Zhejiang Governmental Quality Award" is the highest quality award in Zhejiang Province established by the People's Government of Zhejiang Province. It is a reward for organizations that engaged in product production, engineering construction, service provision, and environmental protection, and have implemented excellent performance management and achieved significant economic and social benefits. The award has been held for seven times. So far, Hanhui Pharma is the second pharmaceutical enterprise to win the honor.
2020-07-01
Hanhui Pharma announced it has entered into a strategic cooperation with WeDoctor Group (Zhejiang) Co., Ltd. The parties will jointly focus on chronic disease prevention, treatment and management, promote digital medical innovation and benefit more doctors and patients.
2020-03-20
Hanhui Pharma announced it has entered into a strategic cooperation agreement with Zai Lab to obtain the exclusive rights to promote Omadacycline Tosilate in mainland China. The collaboration, based on rich experience of Hanhui Pharma in promoting anti-infective products and leading pharmaceutical research and development capabilities of Zai Lab, will accelerate patients' access to Omadacycline Tosilate, the world's leading innovative anti-infective drug, thereby contributing to improving national health, extending human life span and improving quality of life.
2020-01-23
On January 23, Hisun Pharma and Hanhui Pharma donated 5,000 Solu-Medrol (Methylprednisolone Sodium Succinate for Injection 40 mg), 500 Junte (Imipenem and Cilastatin Sodium for Injection 1.0 g) and 100 Lixing (Tigecycline for Injection) for Wuhan Pulmonary Hospital, which could benefit 400 patients.
2020-01-20
Hanhui Pharma has reached a strategic cooperation agreement with Sinopharm Chuankang Pharmaceutical Co., Ltd. Since January 1, 2020, Zhejiang Ruihai Medicine Co., Ltd., a subsidiary of Hanhui Pharma, has been granted the exclusive right to promote, advertise and distribute Miwei® (Midodrine Hydrochloride Tablets) in mainland China, i.e. it has the resale and redistribution rights for the product. Miwei® (Midodrine Hydrochloride Tablets) is an exclusive, medically insured product for the treatment of hypotension and female stress urinary incontinence in China.
